The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Ranked by engagement

Top topics — all time page 31

Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.

1,535 topics · page 31 of 40

TopicParticipantsRepliesViewsActivity
Personal or family history of medullary thyroid carcinoma
Personal or family history of medullary thyroid carcinoma Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
PWJVCSTNSD+31 37 709 26d
What published stability data actually covers, and what it does not — what changed since
What published stability data actually covers, and what it does not — what changed since — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question with the…
ALNBANTI 3 43k 6mo
[2026 update] Conference abstracts as evidence: the weakest common citation
Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-4 ( JAMA , 2024) and finding…
JVVNJB 2 48k 7mo
[2026 update] Hello from a laboratory that does not do peptides
Hello from a laboratory that does not do peptides Writing it up because I had to work it out twice and would rather nobody else did. Lower-stakes topic, but the sourcing rule still applies if anyone makes a…
BWKKLA 2 49k 4mo
A newcomer's list of things that confused me, and the fixes
A newcomer's list of things that confused me, and the fixes — setting out what I have, and where I think it stops being reliable. Question in the title. Context below, and I have tried to include the things…
JRSSZOCRRV+9 13 34k 12mo
Coming back to: Reading a meta-analysis you disagree with, fairly
Reading a meta-analysis you disagree with, fairly Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim I do…
TVBDJIPMCT+30 34 9.3k 17mo
AOD-9604 and the fragment hypothesis, revisited — does this still hold?
The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024)…
NLKKNRPFI+7 11 31k 19h
Insurance and replacement policies, compared — the long version
Insurance and replacement policies, compared — the long version — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately…
THIIBNMA+29 33 4.9k 9mo
Coming back to: Injection-site reactions: describing them precisely enough to be useful
On the subject in the title: Injection-site reactions: describing them precisely enough to be useful Working notes rather than a conclusion. Reporting something rather than asking about it, in case the…
NDOBGRARBD+21 25 22k 8mo
Peer-to-peer review: what actually happens on the call — one year on
Peer-to-peer review: what actually happens on the call — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…
TDYMHESTTK+2 6 41k 5mo
About the Contraindications category
Absolute and relative contraindications, and the conditions that change the calculus. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
TVSLETKFCC+6 10 35k 14mo
Random versus fixed effects: choosing rather than defaulting
Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before posting;…
NPFSMLAJS+16 20 22k 13mo
Why side effects reset at each escalation and that is not a failure — the long version
The question in the title: Why side effects reset at each escalation and that is not a failure — the long version I will give what I have already checked below so nobody repeats it. Reporting something rather…
CCKSH 2 46k 17mo
An ABAB design with a data table and honest limitations
An ABAB design with a data table and honest limitations Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it before…
SSDSEF 2 45k 5mo
Bleeding at the injection site: normal, and what to do about it — does this still hold?
Bleeding at the injection site: normal, and what to do about it — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Reporting something rather than…
BONKOOPMDS+20 24 16k 15mo
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on
Asking directly, because I could not find a straight answer: Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited…
EFIEBMMNB+16 20 18k 2mo
About the Receptor biology category
GLP-1, GIP, glucagon and amylin receptor signalling, bias, desensitisation and central versus peripheral action. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
OBDOSOIKP+6 10 34k 20d
How this community labels and discusses unrefereed work — the long version
Asking directly, because I could not find a straight answer: How this community labels and discusses unrefereed work — the long version I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a…
ITLCNBBI+18 23 21k 2mo
Reading an MS report that only gives you a single number — the long version
Reading an MS report that only gives you a single number — the long version — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I…
TTRAK 2 47k 18mo
Confounding by indication, explained with a concrete example
On the subject in the title: Confounding by indication, explained with a concrete example Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-2 ( N Engl J Med ,…
TVARBDSBCD+21 25 21k 11mo
I have no scientific background — can I still follow the analytics categories?
The question in the title: I have no scientific background — can I still follow the analytics categories? I will give what I have already checked below so nobody repeats it. I want to check my reasoning…
CTMECCAAPS+29 40 1.4k 12d
Introducing myself: pharmacist, sceptic, reluctant participant
Introducing myself: pharmacist, sceptic, reluctant participant Writing it up because I had to work it out twice and would rather nobody else did. Lower-stakes topic, but the sourcing rule still applies if…
IJRJSATCC+13 17 23k 2mo
Insomnia at a dose step: reported experiences
On the subject in the title: Insomnia at a dose step: reported experiences Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference and I…
MMIDFPVMSS+20 24 18k 8mo
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — does this still hold?
Asking directly, because I could not find a straight answer: How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — does this still hold? Structured report rather than an opinion, following the…
EDKSVCDBS+24 28 8k 1mo
Travelling with an injectable: documentation and practicalities
Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting an access outcome, dated, because everything…
CHATJSFEB+37 42 2.1k 1d
Excipient function in a licensed injectable
Excipient function in a licensed injectable Writing it up because I had to work it out twice and would rather nobody else did. Posting the method first, because I know what the first three replies will…
VSEMEKCNRO+3 7 36k 14mo
Validating a calculator against hand arithmetic
Validating a calculator against hand arithmetic Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like it checked.…
IGMABMKAP+17 21 12k 3mo
Needle changes between doses on a reusable pen — does this still hold?
Needle changes between doses on a reusable pen — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on this and I…
NATAALOPM+1 5 38k 13mo
Follow-up: UK access routes, dated and sourced
On the subject in the title: UK access routes, dated and sourced Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of May 2026, in…
APSRNVEOVF+10 14 27k 2d
Journal club: the retatrutide phase 2 obesity paper
Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
LFVDAERASV+7 11 33k 7mo